Advertisement
Table 1 Patient characteristics in genetic sub-study participants versus non-participants
| Consented to use of DNA | |||
|---|---|---|---|
| Yes (n = 3,484) | No (n = 856) | P-value | |
| Demographics | |||
| Age | 58.9 ± 12.2 | 59.8 ± 12.7 | 0.038 |
| White/Caucasian race | 2,342 (67.4%) | 573 (67.3%) | 0.981 |
| Male | 2,347 (67.4%) | 551 (64.4) | 0.095 |
| Language | 0.293 | ||
| English | 3,353 (98.4%) | 823 (97.9%) | |
| Spanish | 55 (1.6%) | 18 (2.1%) | |
| Missing | 76 | 15 | |
| Ethnicity | 0.870 | ||
| Hispanic/latino | 217 (6.4%) | 54 (6.6%) | |
| Non-hispanic/latino | 3,175 (93.6%) | 770 (93.4%) | |
| Unknown | 92 | 32 | |
| Low social support | 612 (18.3%) | 109 (13.1%) | < 0.001 |
| Missing | 133 | 23 | |
| REALM-R score ≤ 6 | 844 (28.5%) | 170 (28.1%) | 0.823 |
| NA, missing, or unknown | 423 | 250 | |
| Socio-economic status | |||
| Completed high school | 2,764 (79.8%) | 656 (76.9%) | 0.058 |
| History of avoiding medical care due to cost | 904 (26.5%) | 184 (21.7%) | 0.004 |
| End-of-month financial situation | <0.001 | ||
| Some money left over | 1,380 (40.4%) | 397 (47.3%) | |
| Just enough to make ends meet | 1,297 (37.9%) | 295 (35.1%) | |
| Not enough to make ends meet | 741 (21.7%) | 148 (17.6%) | |
| Medical history | |||
| BMI | 29.8 ± 10.2 | 29.0 ± 6.5 | 0.025 |
| Chronic heart failure | 302 (8.7%) | 70 (8.2%) | 0.646 |
| Dyslipidemia | 1,721 (49.4%) | 407 (47.5%) | 0.332 |
| Hypertension | 2,318 (66.5%) | 575 (67.2%) | 0.722 |
| Prior MI | 710 (20.4%) | 202 (23.6%) | 0.038 |
| Cancer | 250 (7.2%) | 62 (7.2%) | 0.946 |
| Diabetes | 1,068 (30.7%) | 268 (31.3%) | 0.710 |
| Presentation | |||
| Final MI diagnosis | 0.568 | ||
| STEMI | 1,475 (42.3%) | 383 (44.7%) | |
| NSTEMI | 1,979 (56.8%) | 465 (54.3%) | |
| BBB/uncertain type | 7 (0.2%) | 2 (0.2%) | |
| Patient not diagnosed with MI | 23 (0.7%) | 6 (0.7%) | |
| Peak troponin | 29.3 ± 76.6 | 25.6 ± 58.1 | 0.187 |
| Medications (arrival and discharge) | |||
| Aspirin on arrival | 1,431 (41.1%) | 353 (41.2%) | 0.930 |
| Beta blocker at DC | 3,109 (89.7%) | 776 (91.4%) | 0.132 |
| Thienopyridine on Arrival | 433 (12.4%) | 113 (13.2%) | 0.541 |
| Statin at DC | 3,030 (87.4%) | 744 (87.6%) | 0.852 |
| Processes of care | |||
| In-hospital cardiac catheterization | 3,222 (92.5%) | 777 (90.8%) | 0.096 |
| In-hospital revascularization | 2,498 (71.7%) | 618 (72.2%) | 0.772 |
| Enrolled in other study | 326 (9.4%) | 70 (8.2%) | 0.283 |
| Length of stay | 5.6 ± 6.4 | 6.0 ± 8.90 | 0.207 |
| Health Status | |||
| SAQ Quality of Life score | 62.2 ± 23.6 | 67.5 ± 23.3 | < 0.001 |
| SAQ Angina Stability score | 43.8 ± 21.8 | 47.1 ± 20.6 | < 0.001 |
| SAQ Physical Limitation score | 85.0 ± 22.6 | 88.4 ± 19.6 | < 0.001 |
| SF-12v2 Mental Component score | 49.6 ± 11.5 | 50.0 ± 11.6 | 0.411 |
| SF-12v2 Physical Component score | 42.0 ± 12.4 | 42.8 ± 12.5 | 0.094 |
| PHQ-9 depression severity | <0.001 | ||
| Not clinically depressed | 1,763 (54.4%) | 539 (65.7%) | |
| Mild depression | 831 (25.6%) | 170 (20.7%) | |
| Moderate depression | 376 (11.6%) | 72 (8.8%) | |
| Moderately severe depression | 191 (5.9%) | 27 (3.3%) | |
| Severe depression | 81 (2.5%) | 12 (1.5%) | |
| Missing | 242 | 36 | |
| GRACE 6 m Mortality Risk score | 100.0 ± 29.81 | 103.0 ± 31.1 | 0.008 |
